Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Endonovo Therapeutics (ENDV) Gross Margin (2018 - 2023)

Endonovo Therapeutics has reported Gross Margin over the past 8 years, most recently at 45.59% for Q3 2023.

  • Quarterly results put Gross Margin at 45.59% for Q3 2023, down 1767.0% from a year ago — trailing twelve months through Sep 2023 was 96.21% (up 9464.0% YoY), and the annual figure for FY2022 was 92.62%, up 1312.0%.
  • Gross Margin for Q3 2023 was 45.59% at Endonovo Therapeutics, down from 100.0% in the prior quarter.
  • Over the last five years, Gross Margin for ENDV hit a ceiling of 100.0% in Q2 2023 and a floor of 2704.11% in Q4 2021.
  • Median Gross Margin over the past 5 years was 74.68% (2020), compared with a mean of 89.51%.
  • Biggest five-year swings in Gross Margin: crashed -239499bps in 2021 and later surged 280011bps in 2022.
  • Endonovo Therapeutics' Gross Margin stood at 68.22% in 2019, then crashed by -553bps to 309.12% in 2020, then tumbled by -775bps to 2704.11% in 2021, then soared by 104bps to 95.99% in 2022, then tumbled by -53bps to 45.59% in 2023.
  • The last three reported values for Gross Margin were 45.59% (Q3 2023), 100.0% (Q2 2023), and 95.44% (Q1 2023) per Business Quant data.